内皮素拮抗剂治疗非动脉炎性前部缺血性视神经病变:ENDOTHELION多中心随机对照试验方案
ENDOTHELION是一项III期、前瞻性、多中心、安慰剂对照、随机双盲临床试验,评估口服波生坦125 mg每日两次共8周治疗急性期非动脉炎性前部缺血性视神经病变(NAAION)的疗效。主要终点为3个月时视野平均偏差变化,计划纳入86例,已入组72例,49例完成随访。
要点
- NAAION患者急性期口服波生坦125 mg每日两次共8周,对照为安慰剂。
- 主要终点为3个月时Humphrey 30-2 SITA标准程序视野平均偏差变化。
- 次要终点包括24个月内视野平均偏差和视力变化、OCT视盘周围视网膜神经纤维层和黄斑神经节细胞层厚度变化、2年双侧化率及生活质量。
核心结论
- 内皮素受体拮抗剂是改善NAAION患者解剖和功能预后的潜在方法。
- 该多中心双盲随机对照试验可评估波生坦对NAAION视神经结构和功能(3个月)、双侧化率(24个月)及耐受性的影响。
研究设计与样本
- III期、干预性、前瞻性、多中心、安慰剂对照、随机双盲临床试验。
- 纳入50岁以上、近期起病(小于21天)的典型NAAION患者,随机分配至口服波生坦125 mg每日两次或安慰剂,治疗8周。
- 治疗期外,患者在2、3、6、12和24个月进行随访。
- 2015年8月起在五所法国大学医院眼科和两个专科眼科中心开始入组,计划纳入86例,截至报告已入组72例,49例完成全部随访。
主要发现
- 主要终点为3个月时视野平均偏差(Humphrey 30-2 SITA标准程序)变化。
- 次要终点包括24个月内视野平均偏差和视力变化、OCT测量的患眼视盘周围视网膜神经纤维层和黄斑神经节细胞层厚度变化、2年NAAION双侧化率及生活质量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nonarteritic anterior ischemic optic neuropathy (NAAION) is a major cause of blindness in individuals over 50 years of age, with no available effective treatment. The oral dual endothelin receptor antagonist, bosentan, increases retinal optic nerve head blood flow in healthy humans and glaucoma patients. The objective of this trial is to assess the efficacy of bosentan administered at the acute stage in improving outcomes in NAAION patients. METHODS: ENDOTHELION (ENDOTHELin antagonist receptor in Ischemic Optic Neuropathy) is a phase III, interventional, prospective, multicentre, placebo-controlled randomised double-blind clinical trial. The primary outcome is change in the visual field mean deviation (MD) at 3 months (Humphrey 30-2 SITA standard programme). Secondary outcomes include MD and visual acuity changes up to 24 months, changes in peripapillary retinal nerve fibre and macular ganglion cell layer thickness in the affected eye, as measured by optical coherence tomography, rate of NAAION bilateralisation at 2 years, and quality-of-life. Patients over 50 years of age presenting with typical NAAION of recent onset (less than 21 days) are randomly assigned to either 125 mg oral bosentan or placebo, twice a day, during 8 weeks. Besides visits during the treatment phase, patients attend follow-up visits at 2, 3, 6, 12 and 24 months. The inclusion of patients began in August 2015 at five French University hospital ophthalmology departments and two specialised ophthalmology centres. It is planned to include 86 patients in this trial. To date we have included 72 patients and 49 have completed the full follow-up process. DISCUSSION: An endothelin receptor antagonist is a potential approach to improving the anatomical and functional prognosis of patients with NAAION. This multicentre double-blind randomised controlled trial is an opportunity to assess (1) the effect of bosentan on the structure and function of the optic nerve in NAAION, at 3 months, (2) the effect of bosentan on the bilateralisation rate at 24 months and (3) the tolerance profile of bosentan in this population. TRIAL REGISTRATION: ClinicalTrials.gov NCT02377271 . Registered on March 3, 2015.
引用
- Chiquet C, Vignal C, Gohier P, et al. Treatment of nonarteritic anterior ischemic optic neuropathy with an endothelin antagonist: ENDOTHELION (ENDOTHELin antagonist receptor in Ischemic Optic Neuropathy)-a multicentre randomised controlled trial protocol. Trials. 2022. PMID: 36309759. doi:10.1186/s13063-022-06786-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。